We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 13, 2014

Intensified Doxorubicin Plus Ifosfamide in Soft-Tissue Sarcoma

The Lancet Oncology


Additional Info

The Lancet Oncology
Doxorubicin Alone Versus Intensified Doxorubicin Plus Ifosfamide for First-Line Treatment of Advanced or Metastatic Soft-Tissue Sarcoma: A Randomised Controlled Phase 3 Trial
Lancet Oncol 2014 Mar 05;[EPub Ahead of Print], I Judson, J Verweij, H Gelderblom, JT Hartmann, P Schöffski, J-Y Blay, J Martijn Kerst, J Sufl iarsky, J Whelan, P Hohenberger, A Krarup-Hansen, T Alcindor, S Marreaud, S Litière, C Hermans, C Fisher, PCW Hogendoorn, A Paolo dei Tos, WTA van der Graaf

Further Reading